“Establishing a Risk Model for Diabetic Nephropathy and Addressing the Therapeutic Effect of  Combined Epalrestat- Dapagliflozin Regimen”, IJKD, vol. 18, no. 05, Oct. 2024, doi: 10.52547/ax1vqh41.